Bifidobacterium adolescentis is a probiotic bacterium naturally found in the human gut, and its supplementation has been explored for gastrointestinal health, including relief of abdominal pain. There is some scientific evidence supporting its use, especially in the context of irritable bowel syndrome (IBS), a condition frequently characterized by abdominal pain.

Several randomized controlled trials and meta-analyses have examined multi-strain probiotic formulations that include B. adolescentis among other species. Some studies have reported a reduction in abdominal pain and discomfort in both adults and children with IBS or functional abdominal pain disorders. For example, a 2018 randomized controlled trial published in Alimentary Pharmacology & Therapeutics found that a probiotic mixture containing B. adolescentis reduced abdominal pain in patients with IBS. Mechanistically, B. adolescentis is thought to modulate gut microbiota, reduce gut inflammation, and improve intestinal barrier function, which may contribute to its beneficial effects.

However, the level of evidence is limited by the frequent use of multi-strain combinations in clinical studies, making it difficult to isolate the effects of B. adolescentis alone. Direct evidence for single-strain B. adolescentis is less robust, and more high-quality, strain-specific trials are needed to confirm its efficacy. Overall, the use of B. adolescentis for abdominal pain is supported by some scientific evidence, but the strength of the evidence is moderate.